|
Dr. Spigelman is the Director of Research and Development for the TB Alliance. Previously Dr. Spigelman spent a decade managing drug R&D at Knoll Pharmaceuticals (a division of BASF Pharma). As Vice President of R&D at Knoll Dr. Spigelman directed clinical development and supervised all R&D activities from basic discovery to regulatory approval. He established global R&D processes as part of Knoll's senior R&D management team oversaw a marked increase in US regulatory filings and approvals and supervised joint R&D programs with pharmaceutical companies. Starting as Director of Oncology and Immunology in 1989 Dr. Spigelman became Vice President of R&D at Knoll until its acquisition by Abbott Laboratories in 2001. Dr. Spigelman received his undergraduate degree from Brown University and his medical degree from the Mt. Sinai School of Medicine where he specialized in Internal medicine and Neoplastic Diseases. Dr. Spigelman holds board certifications from the American Board of Internal Medicine the American Board's Subspecialty Board of Medical Oncology and the American Board of Preventive Medicine and was the recipient of the American Cancer Society Clinical Oncology Career Development Award (1985-1988). | 